awmsg logo



travoprost (Travatan®)


Reference No. 2601

Publication date:
18/11/2015


Appraisal information

travoprost (Travatan®) 40 micrograms/ml eye drops


Company: Alcon Laboratories (UK) Ltd
BNF category: Eye
NMG meeting date: 09/09/2015
AWMSG meeting date: 21/10/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3115
Ministerial ratification: 17/11/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Travoprost (Travatan®) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download